Bio Pharma Dive

APRIL 13, 2023

The Danish drugmaker nearly doubled the 2023 forecasts for Wegovy and Ozempic in the latest indicator of the sales potential of an emerging and competitive class of weight loss drugs.

Sales 324

Sales Drugs 324

Pharmaceutical Technology

JULY 31, 2023

Pharma sales have undergone a seismic transformation after Covid-19, with the adoption of artificial intelligence tools.

Sales 246

Sales 246

Bio Pharma Dive

NOVEMBER 9, 2022

While many companies are still unsure of the Inflation Reduction Act's effects, some have begun to warn investors about the likelihood of lower sales and reduced profitability.

Sales 317

Sales Development Drugs 317

Bio Pharma Dive

NOVEMBER 3, 2022

The biotech dialed back its financial projections after reporting lower-than-expected sales for the shot, which currently remains the company’s only marketed product.

Sales 294

Sales Vaccination Vaccine Production 294

Pharmaceutical Technology

MARCH 2, 2023

Merck has reported an increase in group net sales by 12.9% The growth in sales was driven by all regions and business sectors, particularly Life Science. in group sales in fiscal 2022. Additionally, due to the acquisition of Exelead, a biopharmaceutical contract development and manufacturing company, sales increased by 0.4%.

Sales 245

Sales Life Science Licensing Licensing 245

Pharmaceutical Technology

FEBRUARY 3, 2023

Merck (MSD outside North America) has reported a 2% increase in worldwide sales to $13.83bn in the fourth quarter (Q4) of 2022 from $13.52bn in the previous year’s quarter. The company’s pharmaceutical sales recorded a 1% rise to $12.18bn compared to $12.03bn in the prior-year quarter. in the same quarter last year.

Sales 246

Sales Engineer Vaccination Vaccine 246

Fierce Pharma

APRIL 5, 2024

Despite Boehringer Ingelheim’s 2021 Humira biosimilar approval being heralded by some analysts as a “landmark achievement” for the field, the drug—dubbed Cyltezo—has struggled to gain traction than | Facing lackluster Cyltezo sales, Boehringer Ingelheim will prune its ranks in the U.S.

Sales 110

Sales Marketing Drugs 110

Fierce Pharma

APRIL 2, 2024

After years of struggling with hurdles such as generic competition and significantly lower-than-expected sales of its top meds, Acorda Therapeutics is hanging up the gloves with a $185 million deal | Merz Therapeutics, in a "stalking horse bid," agreed to pick up Acorda's Parkinson's disease med Inbrija and multiple sclerosis drug (..)

Sales 114

Sales Drugs 114

Bio Pharma Dive

JANUARY 6, 2023

The gene therapy developer will receive $95 million from Bristol Myers Squibb, slightly less than it got in the recent sale of another priority review voucher.

Sales 305

Sales Gene Therapy Gene Development 305

Bio Pharma Dive

AUGUST 3, 2023

Sales of the company’s COVID-19 vaccine plummeted 94% year over year. But executives believe newer products can help revenue rebound.

Sales 246

Sales Vaccination Vaccine Production 246

Bio Pharma Dive

JULY 27, 2022

A manufacturing issue for Breyanzi, meanwhile, impacted sales. Demand has increased faster than Bristol Myers can make Abecma, although the company said supply is improving.

Sales 286

Sales Production Manufacturing 286

Bio Pharma Dive

JANUARY 24, 2023

The drugmaker reported fourth quarter revenue that fell short of forecasts, but reiterated confidence in reaching a $60 billion pharmaceutical sales goal.

Sales 300

Sales Drugs 300

Bio Pharma Dive

DECEMBER 5, 2023

The company expects its pharmaceutical division to deliver 20 new medicines through the end of the decade, including several it believes could earn peak annual sales of more than $5 billion.

Sales 161

Sales Medicine Drugs 161

Bio Pharma Dive

OCTOBER 26, 2023

Company shares fell Thursday as the company adjusted its medium-term guidance for sales of new products like Reblozyl, Camzyos and Abecma.

Sales 169

Sales Drugs Production 169

Fierce Pharma

MARCH 20, 2024

Sales came to 1.5 Four months ago, when BioNTech slashed its 2023 revenue projection from 5 billi | When BioNTech reported its fourth-quarter earnings Wednesday, it was another harsh reminder of the plummeting demand for COVID-19 vaccines. billion euros ($1.6 billion) for the fourth quarter and 3.8 billion euros ($4.1

Sales 132

Sales Vaccination Vaccine 132

Bio Pharma Dive

APRIL 18, 2023

Revenue topped analyst forecasts on strong market performance from the pharma’s multiple myeloma treatments, as well as the last quarter of significant COVID-19 vaccine sales.

Sales 217

Sales Vaccination Vaccine Drugs 217

Bio Pharma Dive

DECEMBER 22, 2021

Leqvio, which Novartis acquired for nearly $10 billion two years ago, arrives with high sales expectations. But uptake could be slow as insurers and doctors weigh the drug's safety and cost-effectiveness.

Sales 342

Sales FDA Approval Doctors Doctor 342

Pharmaceutical Technology

AUGUST 23, 2023

Physicians with experience with using AI in their practices were more open to sales representatives using AI to personalise messaging.

Sales 130

Sales 130

Bio Pharma Dive

AUGUST 23, 2022

The biotech successfully brought two medicines to market, but shares have lost most of their value amid sluggish sales.

Sales 278

Sales Medicine Drugs Marketing 278

Bio Pharma Dive

APRIL 2, 2024

Stalking horse bidder Merz Therapeutics could get rights to Acorda’s three marketed drugs if its $185 million proposal holds.

Sales 294

Sales Marketing Drugs 294

Bio Pharma Dive

OCTOBER 28, 2021

But sales could climb even higher if it works as a preventive treatment too. Executives based their projections on contracts already in place for the drug, known as molnupiravir.

Sales 306

Sales Drugs 306

Bio Pharma Dive

MAY 4, 2022

The trajectory of COVID-19 vaccine sales is now harder to predict amid questions about the rollout of additional doses and whether purchasing in the U.S. might shift from the federal government to private payers.

Sales 269

Sales Vaccination Vaccine 269

Fierce Pharma

APRIL 16, 2024

For the first time, Johnson & Johnson has reported sales numbers for its novel multiple myeloma treatment Tecvayli and they indicate that the bispecific, which was approved in October 2022, is | For the first time, Johnson & Johnson is reporting sales of its multiple myeloma drug Tecvayli, which is off to a strong launch and contributing to (..)

Sales 72

Sales Drugs 72

Bio Pharma Dive

AUGUST 17, 2022

The federal government will begin the transition as early as this fall, clearing the way for drugmakers to control sales and distribution of their shots and therapeutics.

Sales 269

Sales Marketing Vaccination Vaccine 269

Pharmaceutical Technology

APRIL 19, 2023

increase in sales to $24.75bn in the first quarter (Q1) of 2023, up from $23.4bn during the corresponding quarter of 2022. In the US, sales of J&J rose by 9.7% During this period, the company’s international sales grew by 1.8% from $12.01bn to $12.23bn, and worldwide sales rose by 5.6%. from $5.15bn in Q1 2022.

Sales 130

Sales Production Drugs 130

Bio Pharma Dive

JULY 21, 2021

billion in sales from its shot this year, despite concerns over protection against variants and significant manufacturing setbacks. The pharmaceutical company expects $2.5

Sales 294

Sales Vaccination Vaccine Manufacturing 294

Bio Pharma Dive

AUGUST 1, 2023

Revenue in the second quarter declined by 53% year over year due to lower sales of Pfizer’s coronavirus vaccine and antiviral, which have been less in demand this year.

Sales 130

Sales Vaccination Vaccine Drugs 130

Pharmaceutical Technology

APRIL 28, 2023

Novo Nordisk’s leading drug Ozempic (semaglutide) is forecast to demonstrate a sales growth of 23% in 2023. Ozempic’s forecast 2023 sales of $12.5bn consolidate its position as the dominant market leader, with projected sales in 2023 54% greater than closest competitor Trulicity (dulaglutide) by Eli Lilly, which anticipates sales of $8bn.

Sales 130

Sales Insulin Marketing FDA Approval 130

Bio Pharma Dive

JANUARY 31, 2023

The company expects yearly revenue from Comirnaty and Paxlovid to fall by nearly two thirds in 2023 amid lower vaccination rates and a shift to private market sales.

Sales 161

Sales Vaccination Vaccine Drugs 161

BioSpace

APRIL 16, 2024

On the heels of a Phase IIb win, Arrowhead Pharmaceuticals’ plozasiran could fulfill a critical unmet need in dyslipidemia treatment bringing in $707 million in sales by 2032, according to data analytics firm GlobalData.

Sales 79

Sales Marketing 79

Bio Pharma Dive

FEBRUARY 2, 2023

Still, fourth quarter sales for Mounjaro were slightly below high Wall Street forecasts and didn’t offset falling revenue from Lilly’s COVID-19 antibodies.

Sales 161

Sales Antibody Drugs 161

Pharmaceutical Technology

OCTOBER 20, 2023

Roche has posted a 7% rise in group sales to SFr14.27bn ($15.91bn) at constant exchange rates (CER) in Q3 2023.

Sales 130

Sales 130

Bio Pharma Dive

FEBRUARY 5, 2021

Sales of the antiviral drug accounted for a quarter of the biotech's product revenue in the fourth quarter, disguising hits to its business elsewhere.

Sales 294

Sales Drugs Production 294

Pharmaceutical Technology

JANUARY 25, 2023

It was an exceptional year for Moderna’s vaccine Spikevax, with forecast sales of $19.5bn in 2022. Currently, Spikevax is the second bestselling Covid-19 vaccine behind Pfizer’s Comirnaty, which is in the leading position, with forecast sales of $37bn in 2022.

Sales 147

Sales Vaccination Vaccine Marketing 147

Bio Pharma Dive

FEBRUARY 23, 2024

The company earned only $3.5 million last year from its Roctavian treatment, far below the $50 million to $150 million range it had forecast eight months ago.

Gene Therapy 300

Gene Therapy Sales Gene 300

Bio Pharma Dive

OCTOBER 18, 2021

The company hopes a "streamlined" sales force can turn around a drug launch that's failed to meet expectations amid tough competition from rival medicines.

Sales 278

Sales Drugs Medicine 278

Pharmaceutical Technology

JULY 21, 2023

Johnson & Johnson (J&J) has reported sales of $25.53bn in Q2 of 2023, indicating an increase of 6.3% as against $24.02bn in Q2 2022.

Sales 130

Sales 130